BOLT Bolt Biotherapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1641281 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-51.3%
TTM net income YoY38.7%
TTM EPS YoY37.1%
Revenue 3-yr CAGR-29.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,098.0%
Net margin-1,034.4%
FCF margin—
EBITDA margin-1,068.0%
Returns
ROE-128.8%
ROA-52.0%
ROIC (approx.)-481.0%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets75.9%
Debt / equity0.00x
Current ratio2.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-2.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.70M | $7.69M |
| R&D expense | $28.53M | $57.47M |
| SG&A expense | $13.79M | $18.46M |
| Operating income | -$36.11M | -$73.05M |
| Pretax income | -$33.38M | -$63.12M |
| Income tax | $0 | $0 |
| Net income | -$33.38M | -$63.12M |
| EBITDA | -$34.82M | -$71.27M |
| EPS (basic) | -17.85 | -33.06 |
| EPS (diluted) | -17.85 | -33.06 |
| Weighted avg. shares (diluted) | 1.87M | 1.91M |
| Balance sheet | ||
| Cash & equivalents | $11.70M | $7.21M |
| Short-term investments | $15.80M | $40.12M |
| Current assets | $30.26M | $50.81M |
| PP&E, net | $1.25M | $3.14M |
| Total assets | $56.75M | $99.63M |
| Current liabilities | $8.44M | $15.86M |
| Total liabilities | $30.24M | $42.43M |
| Shareholders' equity | $26.50M | $57.20M |
| Shares outstanding | 1.92M | 1.92M |
| Cash flow statement | ||
| Operating cash flow | -$39.85M | -$61.29M |
| Capital expenditure | $72,000 | $41,000 |
| Free cash flow | -$39.92M | -$61.33M |
| Investing cash flow | $44.30M | $57.58M |
| Financing cash flow | $19,000 | $108,000 |
| Depreciation & amortization | $1.29M | $1.78M |
| Stock-based compensation | $2.78M | $7.41M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.